Drug name - Akynzeo
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6297375 | HELSINN HLTHCARE | 4-phenyl-pyridine derivatives |
Mar, 2023
(5 months from now) | |
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(12 years from now) | |
| CN107001275A | HELSINN HLTHCARE | Form Of Nk-1 Antagonist |
Nov, 2019
(2 years ago) | |
| CN1142144C | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| CN1270959A | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| IN215447B | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| IN200000144I4 | HELSINN HLTHCARE | 4-Phenyl-Pyridine Derivatives |
Feb, 2020
(2 years ago) | |
| EP1394150A1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1394150B1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1035115B1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| EP1035115A1 | HELSINN HLTHCARE | 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists |
Feb, 2020
(2 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(8 years from now) | |
| US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(8 years from now) | |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG;EQ 0.5MG BASE | CAPSULE;ORAL | Prescription |
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(9 years from now) | |
| US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(9 years from now) | |
| US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(9 years from now) | |
| US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(9 years from now) | |
| CN104053652A | HELSINN HLTHCARE | 4-Phenyl Pyridine For Treatment Of Nk-1 Receptor Related Disease |
Nov, 2021
(10 months ago) | |
| CN106518924A | HELSINN HLTHCARE | For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases |
Nov, 2032
(10 years from now) | |
| CN106986822A | HELSINN HLTHCARE | For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases |
Nov, 2032
(10 years from now) | |
| CN106986822B | HELSINN HLTHCARE | Substituted 4-Phenylpyridine For The Treatment Of Nk-1 Receptor Related Diseases |
Nov, 2032
(10 years from now) | |
| CN106518924B | HELSINN HLTHCARE | 4 For Treating Substituted-Phenyl Pyridine Nk-1 Receptor Associated Diseases |
Nov, 2032
(10 years from now) | |
| IN201404907P4 | HELSINN HLTHCARE | Substituted-4- Phenyl Pyridines For The Treatment Of Nk 1 Receptor Related Diseases |
Nov, 2032
(10 years from now) | |
| IN324179B | HELSINN HLTHCARE | Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases |
Nov, 2032
(10 years from now) | |
| EP2785706A1 | HELSINN HLTHCARE | Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases. |
Nov, 2032
(10 years from now) | |
| EP2785706B1 | HELSINN HLTHCARE | Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases. |
Nov, 2032
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(8 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(8 years from now) | |
| US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(9 years from now) | |
| US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(9 years from now) | |
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(14 years from now) | |
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
| EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.